N
Najat C. Daw
Researcher at University of Texas MD Anderson Cancer Center
Publications - 140
Citations - 5461
Najat C. Daw is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Sarcoma & Cancer. The author has an hindex of 37, co-authored 126 publications receiving 4480 citations. Previous affiliations of Najat C. Daw include Children's National Medical Center & University of Tennessee.
Papers
More filters
Journal ArticleDOI
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Xiang Chen,Armita Bahrami,Alberto S. Pappo,John Easton,James T. Dalton,Erin Hedlund,David H. Ellison,Sheila A. Shurtleff,Gang Wu,Lei Wei,Matthew Parker,Michael Rusch,Panduka Nagahawatte,Jianrong Wu,Shenghua Mao,Kristy Boggs,Heather L. Mulder,Donald Yergeau,Charles Lu,Li Ding,Michael N. Edmonson,Chunxu Qu,Jianmin Wang,Yongjin Li,Fariba Navid,Najat C. Daw,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Jinghui Zhang,Michael A. Dyer +30 more
TL;DR: The authors performed whole-genome sequencing of DNA from 20 osteosarcoma tumor samples and matched normal tissue in a discovery cohort, as well as 14 samples in a validation cohort.
Journal ArticleDOI
Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies.
Carlos Rodriguez-Galindo,Tiebin Liu,Matthew J. Krasin,Jianrong Wu,Catherine A. Billups,Najat C. Daw,Sheri L. Spunt,Bhaskar N. Rao,Victor M. Santana,Fariba Navid +9 more
TL;DR: A critical review of data from past treatment eras is needed to identify clinically relevant risk groups in patients with Ewing sarcoma.
Journal ArticleDOI
Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
Clinton F. Stewart,Markos Leggas,John D. Schuetz,John C. Panetta,Pamela J. Cheshire,Jennifer K. Peterson,Najat C. Daw,Jesse J. Jenkins,Richard J. Gilbertson,Glen S. Germain,Franklin C. Harwood,Peter J. Houghton +11 more
TL;DR: It is concluded that gefitinib may modulate SN-38 activity at the cellular level to reverse tumor resistance mediated by ABCG2 through inhibiting drug efflux and may be used potentially in humans to modulate the oral bioavailability of a poorly absorbed camptothecin such as irinotecan.
Journal ArticleDOI
Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
Heribert Juergens,Najat C. Daw,B. Geoerger,Stefano Ferrari,Milena Villarroel,Isabelle Aerts,Jeremy Whelan,Uta Dirksen,Mary L. Hixon,Donghua Yin,Tao Wang,Stephanie Green,Luisa Paccagnella,Antonio Gualberto,Antonio Gualberto +14 more
TL;DR: Figitumumab had modest activity as single agent in advanced Ewing sarcoma and a strong association between pretreatment serum IGF-1 and survival benefit was identified.
Journal ArticleDOI
Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer
Hiroto Inaba,R. B. Khan,F. H. Laningham,Kristine R. Crews,Kristine R. Crews,C H Pui,Najat C. Daw +6 more
TL;DR: Acute MTX toxicity often manifests as fluctuating neurologic symptoms with alternating hemispheric involvement, and restricted diffusion on DWI is a reliable early sign of acute MTX encephalopathy and resolves as clinical status improves, despite the persistence of subtle abnormalities on MRI.